Obermatt

MiMedx

NAQ:MDXG · US6024961012
BiotechnologyMedium

360

77
Profit price5
Owner Earnings Yield93
Dividend Yield1
Price/Sales59
EV / Gross Profit94
Price/Book50
Return on Capital86
Cash Return on Capital92
Return on Equity89
EBIT Margin62
Gross Profitability100
Accruals49
Owner Earnings Margin80
Sales growth7
Profit Growth43
Long-Term EPS Growth37
Reinvestment81
Price momentum14
Debt load82
Refinancing67
Debt Payback100
Liquidity96
Analyst ratings83
Opinion Changes50
Price Target Upside22
Market mood65
Value Creation12/20creating some value
  • Creates more value than its capital costs
  • Owner earnings growing
  • Owner earnings per share growing
  • Reinvests at strong returns
  • Solid earnings base

What this means

MiMedx clears its cost of capital, but the record is mixed across the five tests. Real value creation, just not yet consistent.

Profile

CountryUSA
IndustryBiotechnology
SizeMedium
TypePublic Company
ExchangeNASDAQCM
Employees774
Websitemimedx.com
ISINUS6024961012
Last UpdateApr 2, 2026
Themes
Chronic DiseasesHealth DiagnosticsBiomedical EngineeringOrthopaedicsSurgeryBiotechnologyHealth CareMarketingMedicalMedical DeviceWellness

Description

MiMedx Group, Inc. (MIMEDX) provides a portfolio of products for applications in the wound care, burn, and surgical sectors of healthcare. MIMEDX has focused on the company’s peer-reviewed scientific and clinical data, intellectual property portfoli…

Analysis

Quality compounder

MiMedx Group, Inc. earns the quality_compounder label: good underlying economics priced fairly, with no obvious bargain or excess. Worth noting: the cash the business generates has lagged behind what the income statement shows.

On valuation, the picture is attractive. The owner-earnings multiple stands at 12.8×; owner earnings: the cash an owner could take out each year.

Growth is tepid; the safety picture is sturdy. The company scores 12/20 on our value-creation score: creating some value.

Flags to be aware of: Some accounting patterns deserve a closer look. Reported profits have run ahead of actual cash for several periods. As always: this describes the company's numbers; it is not a recommendation.

360° rank · history

1007550250
69
2026

All-time high

71

Mar 2026

All-time low

69

Jun 2026

Average rank

70

across all years

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023
Price/Sales
59
Price/Earnings
1
Price/Book
50
Dividend Yield
1
Value (overall)
15

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare MiMedx with its peers
Organogenesis
NAQ:ORGO
75
CountryUSA
IndustryBiotechnology
SizeMedium
Full Stock Analysis →
Medline
NSQ:MDLN
33
CountryUSA
IndustryHealth Care Equipment & Supplies
SizeX-Large
Full Stock Analysis →
Pioneer Power Solutions
NAQ:PPSI
16
CountryUSA
IndustryElectrical Equipment
SizeSmall
Full Stock Analysis →
Xeris Pharmaceuticals
NSQ:XERS
70
CountryUSA
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →
SANUWAVE Health
NMQ:SNWV
33
CountryUSA
IndustryHealth Care Equipment & Supplies
SizeSmall
Full Stock Analysis →
Pro-Dex
NAQ:PDEX
83
CountryUSA
IndustryHealth Care Equipment & Supplies
SizeSmall
Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100
Learn More →